SCM
WVE icon

Squadron Capital Management’s Wave Life Sciences WVE Stock Holding History

Squadron Capital Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-175,000
Closed -$2.98M – 48
2025
Q4 		$2.98M Buy
+175,000
New +$1.78M 1.26% 25

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
GP
GSK plc London $602M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Squadron Capital Management's WVE Position: Q1 2026 in Review

Squadron Capital Management sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 175,000 shares — an estimated $2.98M sold.

Squadron Capital Management first reported a position in WVE in Q4 2025 and held it in 1 quarter. The position peaked at $2.98M in Q4 2025. 232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Squadron Capital Management reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Squadron Capital Management sold 175,000 Wave Life Sciences shares in Q1 2026, an estimated $2.98M.
  • Squadron Capital Management first reported a position in Wave Life Sciences in Q4 2025 and held it in 1 quarter.
  • Squadron Capital Management's Wave Life Sciences position peaked at $2.98M in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.